Drug Trial Radar · NCT02269917
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
Last checked: Nov 19, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,149
Actual
Start
Mar 2015
Primary completion
Feb 2017
Study completion Oct 2020
Sponsor
- Lead sponsor
- Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1 ribonucleic acid \[HIV-1 RNA\] concentrations less than \[\<\] 50 copies per milliliter \[copies/mL\]) HIV-1 infected participants.
Conditions
- Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAFDrug
Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
Boosted Protease Inhibitor (bPI)Drug
Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
FTC/TDFDrug
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48Time frame: Through Week 48
Locations
79 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Bakersfield, California
Site not named
Beverly Hills, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Washington D.C., District of Columbia
Site not named
Fort Lauderdale, Florida
Site not named
Ft. Pierce, Florida
Site not named
Orlando, Florida
Site not named
West Palm Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Savannah, Georgia
Site not named
Chicago, Illinois
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Berkley, Michigan
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Hillsborough, New Jersey
Site not named
Newark, New Jersey
Site not named
Somers Point, New Jersey
Site not named
Santa Fe, New Mexico
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Providence, Rhode Island
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
Fort Worth, Texas
Site not named
Houston, Texas
Site not named
Longview, Texas
Site not named
Seattle, Washington
Site not named
Antwerp, Belgium
Site not named
Brussels, Belgium
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.